Adrenal disorders affect the glands above the kidneys that produce hormones involved in stress responses, blood pressure, and salt balance. They include adrenal insufficiency, Cushing syndrome caused by excess cortisol, and primary aldosteronism caus...
Search Bar & Filters
Found 42 Actively Recruiting clinical trials
Actively Recruiting
Researchers are studying adrenal tumor removal surgeries using a high-definition 3D laparoscopic system to improve outcomes compared to traditional 2D laparoscopy. This observational study explores the benefits of using 3D imaging, which offers better depth perception and spatial orientation, potentially reducing errors, fatigue, and operating time during adrenalectomies. The study focuses on both benign and malignant adrenal tumors. The surgery uses a 3D laparoscopic system where all operating room personnel wear polarized glasses to see stereoscopic images. Dissection is performed with a hybrid energy device called Thunderbeat. The study observes patients who underwent unilateral 3D laparoscopic adrenalectomy between 2013 and 2033, without comparing to other surgical approaches. Participants have their surgical outcomes monitored up to 30 days after surgery, including complication rates and length of hospital stay. Researchers also evaluate factors like bleeding, operative time, use of drainage, and differences in morbidity related to obesity, previous surgeries, patient age, anesthesia risk scores, tumor size, diagnosis, and tumor side. The study collects detailed data to understand how 3D laparoscopy affects adrenalectomy results over time.
Actively Recruiting
Researchers are evaluating the incidence of adrenal insufficiency in patients with endogenous Cushing syndrome who are treated with osilodrostat combined with glucocorticoid replacement therapy. The study also aims to assess new steroid biomarkers for dosing adequacy, and to monitor the safety, durability, and clinical improvement during treatment. The treatment starts with a Phase 1 titration period where participants take osilodrostat with added methylprednisolone as replacement therapy. Osilodrostat dosage is gradually increased to reach targeted cortisol levels, while participants are closely monitored. After reaching maintenance doses, participants enter Phase 2, a maintenance phase lasting 48 weeks, during which cortisol levels and other clinical measures are periodically assessed. Participants provide informed consent and receive frequent assessments including blood and urine tests for cortisol and steroid profiles. Communication with study staff is frequent in the early treatment phase to monitor for adrenal insufficiency signs. Outcome measures include adrenal insufficiency events, cortisol levels, symptom frequency, blood pressure, weight changes, medication use, and quality of life scores. The study lasts approximately 48 weeks from the first osilodrostat dose.
Actively Recruiting
Neuroendocrine neoplasms NENs are rare cancers found in various body parts like the gastrointestinal tract, pancreas, lungs, and adrenal glands. These cancers often have a high risk of returning and low survival rates, highlighting the need for better treatments. This trial evaluates a new drug called ADCT-701 in adults with NENs, adrenocortical carcinoma, or malignant peripheral nerve sheath tumors to find the maximum tolerated dose. Participants receive ADCT-701 through an intravenous infusion on the first day of a 21-day treatment cycle. Dosing will be adjusted based on tolerance in a dose-finding design with up to ten dose levels. Clinic visits occur frequently during the first two cycles, then less often in subsequent cycles, with treatment lasting up to two years. The study includes physical exams, blood and urine tests, imaging scans, heart function tests, and possibly tumor biopsies. Participants will be followed after treatment ends with regular clinic visits over several years. These visits include physical exams, heart and blood tests, and imaging scans to monitor health and the drugs effects. The study aims to measure the drugs safety, maximum tolerated dose, anti-tumor activity, pharmacokinetics, and immune response over time, with total participation lasting up to five years from treatment start.
Actively Recruiting
This clinical trial investigates the safety and recovery benefits of tubeless laparoscopic adrenalectomy in patients undergoing adrenal gland removal surgery. The study aims to answer whether avoiding drainage tubes after surgery helps patients recover more quickly, focusing on pain, the time to first get out of bed, and the recovery of intestinal function. It is a prospective, single-center, randomized controlled study enrolling 200 patients who need laparoscopic adrenalectomy. Participants are randomly assigned to one of two groups one group receives surgery without drainage tubes tubeless group, and the other group has drainage tubes placed after surgery drainage group. The study compares outcomes such as pain scores, blood tests, and recovery indicators between these groups. Follow-up includes adrenal ultrasounds at one and six months post-surgery to monitor recovery and safety. During the study, participants will have blood tests and assessments of pain, time to mobilization, and intestinal function for the first three days after surgery. Researchers will also monitor for complications like fever and wound infections. Follow-up ultrasound exams at one and six months will help evaluate longer-term recovery. The trial uses block randomization and collects data to assess whether tubeless surgery promotes faster and safer recovery after adrenalectomy.
Actively Recruiting
Researchers are evaluating the safety, tolerability, and early signs of effectiveness of DS9051b in adults with advanced or metastatic adrenocortical carcinoma ACC and metastatic castration-resistant prostate cancer mCRPC. This first-in-human phase 1 trial aims to find the highest dose that can be given safely and to understand how the drug behaves in these patients. The study is sponsored by Daiichi Sankyo and focuses on these two serious cancer types. Participants will receive DS9051b orally as part of a dose escalation process to determine the maximum tolerated dose and the best dose for further study. The trial is open-label and involves multiple centers. All participants receive the experimental drug, and there are no placebo or comparator groups. The treatment period can last up to 50 months, during which various doses will be tested and adjusted based on safety and tolerability. Throughout the study, participants will be closely monitored for side effects, including dose-limiting toxicities and serious adverse events. Researchers will assess treatment responses using imaging and clinical evaluations, documenting disease control and progression. Visits include laboratory tests, physical exams, and assessments of cancer status. The study will also measure progression-free survival and duration of response over the course of up to 50 months, with ongoing safety follow-up during this period.
Actively Recruiting
Glucocorticoids are hormones that help control inflammation and regulate the immune system. In children with blood cancers like acute lymphoblastic leukemia ALL and lymphoblastic lymphoma LBL, these hormones are given as medications to quickly reduce cancer cells. However, this treatment can suppress the bodys natural glucocorticoid production, leading to a deficiency that increases infection risks and is hard to detect due to overlapping chemotherapy side effects. This study aims to understand how often and for how long this deficiency occurs in children with these cancers and to identify those at higher risk. The study observes children diagnosed with ALL or LBL who are treated with glucocorticoids for at least 21 consecutive days. Regular low-dose ACTH tests will be performed during and after treatment to assess the bodys natural glucocorticoid production. These tests are done only when children already have venous access and are hospitalized for treatment, minimizing extra burden. The study follows participants from enrollment until three months after their last glucocorticoid dose. Participants will be monitored through these ACTH tests to detect adrenal insufficiency and its duration. The main outcome measured is the occurrence of adrenal insufficiency, with a secondary focus on how long it lasts. The study involves children up to 18 years old and takes place at two childrens hospitals. The goal is to improve understanding and management of glucocorticoid deficiency during and after cancer treatment, with careful attention to the safety and comfort of the children involved.
Actively Recruiting
Researchers are investigating the causes and development of adrenal tumors, which include adrenocortical carcinoma, Cushing syndrome, Conn syndrome, and pheochromocytoma. The study aims to better understand how these tumors form and to evaluate new treatment options for patients with malignant adrenal tumors, addressing the limited current therapies available. This observational research is sponsored by the University of Wuerzburg and has been ongoing since 2002. Participants in the study may provide tumor material and related biological samples if they have adrenal tumors. Additionally, biological samples are collected from patients without adrenal tumors to serve as comparison controls. The research does not involve experimental treatments but focuses on collecting and analyzing biospecimens to explore tumor biology and potential therapies. Throughout the study, participants contribute by providing tumor and biosample materials. Researchers analyze these samples to study tumor characteristics and evaluate possible new treatments. There are no specific outcome measures listed. The study is observational, with no assigned treatments, and aims to gather information to support future therapeutic developments. Participants involvement duration varies, and the study is expected to continue until December 2032.
Actively Recruiting
Researchers are evaluating how well a combination of cabozantinib and pembrolizumab works for patients with adrenal cortical cancer that has spread locally, to other parts of the body, or cannot be removed by surgery. This phase II trial studies cabozantinib, which may reduce tumor growth and blood vessel formation, alongside pembrolizumab, an immunotherapy that helps the immune system attack cancer cells. The goal is to see if this combination is more effective than these drugs used alone. Participants receive cabozantinib orally once daily on days 1 to 21 of each 21-day cycle. Pembrolizumab is given intravenously over 30 minutes on day 1 of each cycle. Treatment continues until the cancer progresses or side effects become unacceptable. Imaging scans like CT or MRI are done at screening and every 12 weeks during the study. Blood samples are collected at screening, during treatment, and at the end. Patients without available tumor tissue undergo a biopsy before treatment. During the study, researchers monitor tumor response using standardized criteria every 12 weeks for up to 2 years. They assess progression-free survival, overall survival, safety, and side effects for up to 2 years. After treatment ends, participants are followed for 28 days and then up to 2 years for long-term monitoring. The study also explores changes in immune cells and inflammatory markers in blood and tissue samples to better understand treatment effects.
Actively Recruiting
Primary aldosteronism PA is a common cause of secondary hypertension, and its diagnosis and treatment pose significant challenges. This research investigates adrenal venous sampling AVS, which is considered the best method to distinguish between different types of PA. The study aims to address clinical, technical, and methodological questions about AVS and to understand how AVS-guided management influences long-term health and biochemical results to improve patient care. Participants with PA will undergo adrenal venous sampling through either the antecubital or femoral vein to identify whether aldosterone overproduction is unilateral or bilateral. This observational study evaluates the AVS procedure itself and its clinical outcomes, refining protocols and standardizing practices to optimize treatment decisions and patient prognosis. Throughout the study, researchers will monitor major cardiovascular events one year after AVS. They will also assess procedure success rates, complications, medication changes, blood pressure, heart and kidney function, and clinical outcomes over multiple years. The follow-up includes assessments at 1, 3, 6, 12, 18 months, and up to 10 years, enabling comprehensive evaluation of long-term effects and safety.
Actively Recruiting
Healthy Volunteer
Researchers are studying primary aldosteronism PA, a condition where the adrenal gland produces too much aldosterone, leading to high blood pressure and low potassium. The study focuses on Black individuals, including African Americans and those of Caribbean descent, to identify genetic causes of PA and understand the effects of these mutations on adrenal tumors and aldosterone production. The research also explores potential medicines to treat PA by blocking inappropriate aldosterone production. Participants include Black adults aged 18 to 70 with difficult-to-control blood pressure or diagnosed PA, as well as relatives aged 7 and older of people with PA. Those with PA or suspected PA undergo initial screening visits lasting 1 to 2 hours and, if eligible, a hospital stay for 7 to 10 days involving various tests such as blood and urine tests, scans, heart and kidney evaluations, and bone density scans. Relatives have a single visit for medical history and blood tests. Treatments, including adrenal gland removal surgery or aldosterone-blocking drugs, may be offered based on test results. During the study, participants undergo evaluations including medical history, physical exams, blood and urine tests, imaging scans, and sample collections such as a small hair sample. Follow-up visits occur 2 to 4 weeks after surgery if performed, and participants may return about one year later for repeat testing. Researchers measure genetic mutations, tumor function, aldosterone levels, and health effects on heart, kidneys, metabolism, bones, and blood clotting. The study aims to improve understanding of PAs impact and identify effective treatments for Black patients.
1-10 of 42
1